Latest Breaking News On - Heavily pretreated patients with relapsed refractory - Page 1 : comparemela.com

The selective CDK9 inhibitor KB-0742 displayed anti-tumor activity and manageable safety as a single agent in heavily pretreated patients with relapsed/refractory, transcriptionally addicted solid tumors, according to data from a phase 1 trial (NCT04718675).

United statesMiguel villalona caleroTherapeutics researchDepartment of medical oncologyInternational conference on molecularEarly phase therapeutics programMolecular targetsMedical oncologyDevelopmental cancer therapeutics programThe selective cdk9 inhibitor kb 0742Heavily pretreated patients with relapsed refractoryRanscriptionally addicted solid tumorsPhase 1 trial nct047186752023 aacr nci eortc international conference on molecular targets and cancer therapeutics